Voyager Therapeutics Inc. (VYGR) Trading Down 1.8%
Voyager Therapeutics Inc. (NASDAQ:VYGR)’s share price fell 1.8% during trading on Thursday . The company traded as low as $15.84 and last traded at $15.97, with a volume of 53,766 shares. The stock had previously closed at $16.26.
A number of research firms recently commented on VYGR. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of Voyager Therapeutics in a research note on Wednesday, June 22nd. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research note on Thursday, May 12th. Stifel Nicolaus began coverage on shares of Voyager Therapeutics in a research note on Thursday, July 14th. They issued a “buy” rating and a $33.00 price objective for the company. Wells Fargo & Co. began coverage on shares of Voyager Therapeutics in a research note on Friday, May 20th. They issued an “outperform” rating for the company. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research note on Wednesday, June 22nd. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Voyager Therapeutics currently has an average rating of “Buy” and an average price target of $30.25.
The stock’s 50 day moving average price is $13.89 and its 200 day moving average price is $11.92. The company’s market capitalization is $409.74 million.
Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Thursday, August 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.03. On average, equities research analysts expect that Voyager Therapeutics Inc. will post ($1.51) earnings per share for the current fiscal year.
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.